Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2474247 | 0.84 | KDM4E (0.41) | NCEH1KMT2ACYP1A2 | |
| SCHEMBL2473232 | 0.81 | ALDH1A1 (0.42) | LMNASMN1; SMN2KMT2ARAB9ATP53 | |
| SCHEMBL4399378 | 0.75 | RAB9A (0.50) | LMNASMN1; SMN2KMT2ARAB9ATP53 | |
| SCHEMBL2908470 | 0.74 | CNR1 (0.36) | LMNASMN1; SMN2KMT2ARAB9ACYP1A2 | |
| SCHEMBL2908107 | 0.73 | FBP1 (0.34) | LMNASMN1; SMN2KMT2ARAB9ATP53 | |
| SCHEMBL2907451 | 0.72 | RAB9A (0.39) | LMNASMN1; SMN2KMT2ARAB9ACYP1A2 | |
| SCHEMBL4173702 | 0.71 | RAB9A (0.38) | LMNASMN1; SMN2KMT2ARAB9ACYP1A2 | |
| SCHEMBL21991455 | 0.71 | CYP2C9 (0.49) | LMNASMN1; SMN2KMT2ARAB9ACYP1A2 | |
| SCHEMBL2904184 | 0.71 | FBP1 (0.36) | SMN1; SMN2RAB9ATP53FBP1 | |
| SCHEMBL3069062 | 0.71 | RAB9A (0.41) | LMNASMN1; SMN2KMT2ARAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1411052-B1 | BENZO-FUSED 5-MEMBERED HETROCYCLE COMPOUNDS,PROCESS FOR PREPARATION OF THE SAME, AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-20070149558-A1 | Benzo-fused 5-membered heterocyclic compounds, their production and use | OHKAWA SHIGENORI | 2007-06-28 | — | — | US | disclosed |
| US-7208495-B2 | Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| US-20040167171-A1 | Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-08-26 | — | — | US | disclosed |
| EP-1411052-A1 | BENZO-FUSED 5-MEMBERED HETROCYCLE COMPOUNDS,PROCESS FOR PREPARATION OF THE SAME, AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149558-A1 | Benzo-fused 5-membered heterocyclic compounds, their production and use | CBR1, DBH, PARK7 | NCEH1 922/4885LMNA 4051/4885SMN1; SMN2 63/4885 |
| US-20040167171-A1 | Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof | CYP8B1, PARK7, OXER1 | NCEH1 278/4885LMNA 3240/4885SMN1; SMN2 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.